Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies (NASDAQ: NSTG) has announced the launch of the Mouse Whole Transcriptome Atlas (WTA) for spatial analysis using its GeoMx Digital Spatial Profiler. This product enhances the GeoMx RNA portfolio, facilitating full transcriptome spatial RNA and high-plex protein analysis. Designed for NGS readout on Illumina sequencers, the WTA broadens applications beyond oncology and immunology to include neuroscience and developmental biology. The technology provides comprehensive insights into gene expression and pathology, supporting critical research in Alzheimer's disease.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported financial results for Q1 2021, highlighting product and service revenue of $31.4 million, a 28% year-over-year growth. Instrument revenue was $11.7 million, up 19%, driven by GeoMx® DSP instruments contributing $7.0 million. Consumables revenue grew 39% to $16.0 million. Cash and short-term investments totaled $409.9 million. The company noted a surge in demand for GeoMx DSP and published 12 new peer-reviewed publications during the quarter.
NanoString Technologies (NASDAQ: NSTG) announced a forthcoming peer-reviewed publication in Nature using its GeoMx® Digital Spatial Profiler (DSP). The study focuses on SARS-CoV-2's impact on human lungs, aimed at understanding COVID-19 pathology to inform therapeutic strategies. Researchers from renowned institutions, including the Broad Institute and Beth Israel Deaconess Medical Center, contributed to creating a comprehensive cell-type atlas from lung autopsy samples. This publication represents the 50th peer-reviewed achievement for NanoString's DSP, emphasizing its significance in advancing biological research.
NanoString Technologies (NASDAQ: NSTG) announced the presentation highlights of spatial biology research at the AACR 2021 meeting to be held from April 10-15, 2021. The GeoMx® Digital Spatial Profiler (DSP) will be featured in eight abstracts, showcasing its capability in profiling RNA and proteins in breast cancer research. Notably, four abstracts will be presented by the GeoMx Breast Cancer Consortium, aiming to create a comprehensive database of novel biomarkers. The DSP has been referenced in numerous publications and provides significant insights into tumor microenvironments and treatment responses.
NanoString Technologies, Inc. (NASDAQ:NSTG) plans to release its first quarter 2021 operating results after market close on May 10, 2021. The company will host a conference call at 4:30 PM ET to discuss the results and provide a business update. Interested parties can register for the call in advance through their website. A replay will be available starting May 10 at 7:30 PM ET until May 17, 2021. NanoString is known for its nCounter® Analysis System, utilized in over 4,000 peer-reviewed publications, and its GeoMx™ Digital Spatial Profiler for RNA and protein profiling.
NanoString Technologies (NASDAQ: NSTG) announced the publication of two peer-reviewed studies utilizing its GeoMx® Digital Spatial Profiler in Nature and Nature Communications. These studies examined SARS-CoV-2 infection using lung tissue from COVID-19 autopsies, analyzing over 1,800 genes. The findings highlight unique immune responses and tissue damage related to COVID-19 progression. Additional insights were gained into the difference in immune cell composition between early and late mortality patients. NanoString's DSP technology continues to showcase its capability in advancing understanding of complex diseases.
NanoString Technologies (NASDAQ:NSTG) has partnered with Doloromics through a Technology Access Program grant aimed at advancing research into chronic pain diseases. This collaboration will leverage NanoString's GeoMx® Digital Spatial Profiler technology to spatially analyze the dorsal root ganglion (DRG). It focuses on delivering high-resolution spatial biology that integrates multi-omics datasets from patient tissues, potentially leading to new therapeutic targets. The partnership emphasizes the significance of spatial profiling in understanding pain mechanisms and drug development.
NanoString Technologies (NASDAQ: NSTG) announced the appointment of Dr. Dana Rollison and Janet George to its board on March 8, 2021. Dr. Rollison, previously at Moffitt Cancer Center, has extensive experience in data science and cancer research, while George brings over 15 years of tech leadership from Oracle and other firms. Their expertise is expected to enhance NanoString's capabilities in spatial biology and big data analytics within life sciences, reflecting the company's commitment to advancing biological research applications.
NanoString Technologies reported a Q4 2020 revenue of $35.7 million, marking a 6% year-over-year growth. Instrument revenue surged 11% to $15.3 million, bolstered by the GeoMx DSP instrument sales. Full-year revenues totaled $111.4 million, reflecting a 7% annual increase. However, consumables revenue declined 18% for the year. The company holds $440.7 million in cash, with a projected 2021 revenue between $140 million and $150 million, indicating a potential growth of 26% to 35%.
NanoString Technologies (NASDAQ: NSTG) announced the launch of its Technology Access Program (TAP) for the Spatial Molecular Imager (SMI), allowing researchers to submit tissue samples for comprehensive data analysis using a 1000-plex RNA panel. The company will showcase its GeoMx Digital Spatial Profiler (DSP) and Whole Transcriptome Atlas (WTA) during the 2021 AGBT conference. The SMI platform enhances genomic research by visualizing thousands of RNAs directly in tissue samples. CEO Brad Gray emphasized the expanded capabilities for spatial biology applications.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
